盟科药业2025年预损2.4亿，上市后连亏四年

Company Dynamics - Shanghai Mengke Pharmaceutical Co., Ltd. (stock code: 688373.SH) is an innovative pharmaceutical company that went public on the STAR Market in August 2022, but has yet to achieve its annual profit targets, with its commercialization process and financial status under scrutiny [2] - For the fiscal year 2025, the company reported a total revenue of 141.77 million yuan, an increase of 8.83% year-on-year; however, the net loss attributable to shareholders reached 241.61 million yuan, with the loss excluding non-recurring items climbing to 250.27 million yuan, indicating significant profitability pressure [2] - During the reporting period, only one product, Kantizolam tablets, achieved commercial sales, and the company's attempts to combine self-operated teams with commercial distribution have not fully materialized, resulting in only modest revenue growth [2] Financial Performance - From 2022 to 2024, the company reported revenues of 48.21 million yuan, 90.78 million yuan, and 130 million yuan respectively, while the net losses for the same periods were 220 million yuan, 420 million yuan, and 440 million yuan [3] - The company acknowledged in its 2024 annual report that current revenues are insufficient to cover R&D and commercialization expenses, and the ongoing losses have not been fundamentally resolved [3] Strategic Initiatives - To address its operational challenges, the company initiated a significant capital operation plan in September 2025, proposing to introduce Nanjing Haiqing Pharmaceutical Co., Ltd. as a strategic investor through a private placement of shares worth 1.032 billion yuan, which would give Haiqing a 20% stake and make it the controlling shareholder [4] - The strategic partnership aims to leverage Haiqing's resources in commercialization to enhance product access and sales in new regions and hospital terminals, with projected sales revenues of 260 million yuan, 388 million yuan, and 600 million yuan from 2026 to 2028 [4] Challenges and Future Outlook - The plan to bring in external strategic investors ultimately fell through in November 2025 due to opposition from major shareholder Genie Pharma, leading to the termination of the private placement [5] - Concerns about liquidity have arisen due to the company's ongoing losses, prompting inquiries from investors regarding the sufficiency of current funds for future operations and potential financing plans [5] - The company stated that it will continue to utilize raised funds, self-funds, or self-raised funds to advance new drug clinical trials and commercialization processes [5]